AC
ARRY

Apex Capital’s Array Biopharma Inc ARRY Stock Holding History

Apex Capital’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,550,000
Closed -$11.4M – 58
2015
Q1 		$11.4M Sell
1,550,000
-452,700
-23% -$3.22M 0.82% 46
2014
Q4 		$9.47M Sell
2,002,700
-1,097,400
-35% -$4.34M 0.66% 44
2014
Q3 		$11.1M Sell
3,100,100
-499,900
-14% -$1.97M 0.79% 44
2014
Q2 		$16.4M Buy
3,600,000
+1,200,000
+50% +$4.96M 1.03% 37
2014
Q1 		$11.3M Sell
2,400,000
-250,000
-9% -$1.26M 0.79% 44
2013
Q4 		$13.3M Buy
2,650,000
+150,000
+6% +$817K 0.88% 43
2013
Q3 		$15.6M Buy
2,500,000
+642,100
+35% +$3.81M 1.11% 40
2013
Q2 		$8.44M Buy
+1,857,900
New +$9.99M 0.58% 60

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apex Capital's ARRY Position: Q2 2015 in Review

Apex Capital sold out of Array Biopharma Inc (ARRY) in Q2 2015, closing a stake of 1,550,000 shares — an estimated $11.4M sold.

Apex Capital first reported a position in ARRY in Q2 2013 and held it in 8 quarters. The position peaked at $16.4M in Q2 2014. 148 funds tracked by Wall St. Rank hold ARRY as of Q2 2015.

  • Apex Capital reported no remaining Array Biopharma Inc position as of Q2 2015 after selling out during the quarter.
  • Apex Capital sold 1,550,000 Array Biopharma Inc shares in Q2 2015, an estimated $11.4M.
  • Apex Capital first reported a position in Array Biopharma Inc in Q2 2013 and held it in 8 quarters.
  • Apex Capital's Array Biopharma Inc position peaked at $16.4M in Q2 2014.
  • 148 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2015.

Based on Apex Capital's 13F filing for Q2 2015, filed 28 Jul 2015.